Dr. Rebecca Paul

Rebecca Paul is a Senior Research Leader at Isomorphic Labs, a digital biology company aiming to redefine drug discovery with artificial intelligence. She studied Natural Sciences at the University of Cambridge before moving to Imperial College London to complete her PhD as part of the Institute of Chemical Biology. Following 6 years at Sosei-Heptares, she moved into the AI drug design space at Benevolent AI, where she worked for 4 years in the neurodegeneration field. Rebecca joined Isomorphic Labs in 2022, where she currently leads the Medicinal Drug Design Group.